International Gastric Cancer Congress | Conference

Sam Klempner, MD, Talks ctDNA for Nonmetastatic Gastric and Esophageal Cancers
April 27, 2022

Sam Klempner, MD, spoke about clinical management and ctDNA for gastrointestinal cancers.

Sam Klempner, MD, Discusses Minimal Residual Disease in Gastrointestinal Cancers
April 18, 2022

Sam Klempner, MD, spoke about the importance of expanding minimal residual disease platforms for patients with gastrointestinal cancers.

Sam Klempner, MD, Reviews ctDNA Role in Gastroesophageal Cancers
April 04, 2022

Sam Klempner, MD, spoke about utilizing ctDNA the treat nonmetastatic gastroesophageal cancers at 2022 IGCC.

Yelena Y. Janjigian, MD, Reviews MSI as a Biomarker in for Localized Gastric Cancer
March 22, 2022

Yelena Y. Janjigian, MD, spoke about which biomarkers were most predictive for treatment of localized gastric cancer.

Yelena Y. Janjigian, MD, Considers Immunotherapy Treatment Options for Gastric Cancer
March 15, 2022

Yelena Y. Janjigian, MD, spoke about using immunotherapy across settings to treat localized gastric cancer.

Laparoscopy Lead to Better OS, Noninferior RFS Vs Open Gastrectomy in Advanced Gastric Cancer
March 10, 2022

Laparoscopy compared with open gastrectomy was found to produce better overall survival outcomes at the 5-year follow-up analysis for patients with advanced gastric cancer.

TILs in Invasive Tumor Margins May Hold a Key to Gastric Cancer Prognosis
March 09, 2022

An analysis presented at 2022 IGCC showed that the level of CD8 + cells in the outer margin of gastric cancer tumors was significantly associated with survival outcomes and could inform prognosis.

Data Show Men With MSI-High Gastric Cancer Have Worse Survival Vs Female Counterparts
March 09, 2022

Men with MSI-high gastric cancer may have shorter overall survival than women, regardless of treatment modality.

Kohei Shitara, MD, Discusses Immunotherapy in Gastric Cancer at 2022 IGCC
March 08, 2022

Kohie Shitara, MD, spoke about the use of immunotherapy in the first-line setting for metastatic gastric cancer.

Low FAM46C Predictive of Inferior Survival Following Curative Resection for Gastric Adenocarcinoma
March 08, 2022

Post-resection survival could be predicted by FAM46C expression in patients with gastric adenocarcinoma.